Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.

Guest writer Reché Jones says it took her years to be diagnosed with relapsing-remitting MS. Now she plans to "keep moving." ...

In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

A longtime couple who coincidentally both have a life-altering disease consider themselves “lucky” to have each other. They ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...

The singer shares how a new treatment for multiple sclerosis has helped him hit the road for the band's 30th anniversary tour ...

Multiple sclerosis (MS) is a chronic autoimmune, neurodegenerative disease that attacks the central nervous system (CNS). These attacks lead to the breakdown of myelin, the protective cover that ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...